PriceTargets.com logo

Kindred Biosciences - KIN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.25 As of 08/27/2021 01:00 AM ET
+0 (0.00%)
Get New Kindred Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Kindred Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.25.

This chart shows the closing price for KIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Kindred Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/23/2021Alliance Global PartnersDowngradeBuy ➝ Neutral
6/17/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral
6/17/2021Lake Street CapitalDowngradeBuy ➝ Hold$12.00 ➝ $9.25
6/17/2021HC WainwrightDowngradeBuy ➝ Neutral$9.00 ➝ $9.25
6/16/2021AegisReiterated RatingBuy ➝ Hold$16.00 ➝ $9.25
5/12/2021Alliance Global PartnersBoost Target$9.25 ➝ $15.25
2/15/2021AegisReiterated RatingBuy
1/26/2021AegisBoost TargetBuy$14.00 ➝ $16.00
12/21/2020Alliance Global PartnersLower Target$10.25 ➝ $9.25
12/1/2020Alliance Global PartnersLower TargetBuy$12.50 ➝ $10.25
8/6/2020HC WainwrightReiterated RatingBuy$9.00
7/29/2020Cantor FitzgeraldLower TargetOverweight$25.00 ➝ $11.00
6/2/2020AegisReiterated RatingBuy
3/17/2020Cantor FitzgeraldReiterated RatingOverweight
3/17/2020Stifel NicolausLower TargetBuy$14.00 ➝ $13.00
3/17/2020HC WainwrightLower TargetBuy$16.00 ➝ $9.00
3/17/2020GuggenheimDowngradeBuy ➝ Neutral
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Kindred Biosciences logo
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: $9.25
Low: $9.24
High: $9.26

50 Day Range

MA: $9.22
Low: $9.08
High: $9.25

52 Week Range

Now: $9.25
Low: $3.46
High: $9.28

Volume

178,496 shs

Average Volume

840,890 shs

Market Capitalization

$420.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Kindred Biosciences?

The following sell-side analysts have issued stock ratings on Kindred Biosciences in the last year: StockNews.com.
View the latest analyst ratings for KIN.

What is the current price target for Kindred Biosciences?

0 Wall Street analysts have set twelve-month price targets for Kindred Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kindred Biosciences in the next year.
View the latest price targets for KIN.

What is the current consensus analyst rating for Kindred Biosciences?

Kindred Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KIN.

What other companies compete with Kindred Biosciences?

Other companies that are similar to Kindred Biosciences include Xencor, Nurix Therapeutics, Dynavax Technologies, Arvinas and Kiniksa Pharmaceuticals. Learn More about companies similar to Kindred Biosciences.

How do I contact Kindred Biosciences' investor relations team?

Kindred Biosciences' physical mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company's listed phone number is (650) 701-7901 and its investor relations email address is [email protected]. The official website for Kindred Biosciences is kindredbio.com. Learn More about contacing Kindred Biosciences investor relations.